215258-13-2

Upstream product

• 16173-52-7 4-formylbenzoyl chloride 
• 58287-76-6 4-(N,N-Dimethylcarbamoyl)benzaldehyde 
• 215258-27-8 (E)-methyl 3-(4-(dimethylcarbamoyl)phenyl)acrylate 
• 619-66-9 4-Carboxybenzaldehyde 
• 160642-45-5 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-3-bromo-2-methylimidazo[1,2-a]pyridine 
• 194928-67-1 (E)-4-(N,N-dimethylcarbamoyl)cinnamic acid 

Relevant academic research and scientific papers

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man

Recently we reported the identification of a series of 8-[[3-(N- acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]-3-halo-2-methytimidazo[1,2- α]pyridines as the first orally active non-peptide bradykinin (BK)B2 receptor antagonists (1-3). Thes

IMIDAZO [1,2-A] PYRIDINES AND THEIR PHARMACEUTICAL USE

The invention relates to novel bradykinin antagonists of the formula: STR1 wherein R 1 is halogen,R 2 and R 3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R 4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R 11, in which R 11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.